Paris, France

Philippe Perrin

USPTO Granted Patents = 25 


 

Average Co-Inventor Count = 3.1

ph-index = 8

Forward Citations = 215(Granted Patents)


Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):Explore Patents

Title: **Philippe Perrin: Innovating Pharmaceutical Science in Paris**

Introduction

Philippe Perrin is a notable inventor based in Paris, France, with a remarkable portfolio of 24 patents to his name. His work predominantly focuses on the field of synthetic progestogens, contributing significantly to pharmaceutical compositions and methods of use that enhance medical therapies.

Latest Patents

Among his latest innovations, Perrin has developed groundbreaking synthetic progestogens, including the compound 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone. This innovation includes not only the chemical formulation but also pharmaceutical compositions that incorporate these compounds for potential medical applications. His recent patents emphasize the therapeutic utility of these synthetic agents, demonstrating his commitment to advancing pharmaceutical science.

Career Highlights

Throughout his career, Philippe Perrin has made significant contributions to the pharmaceutical industry, having worked with reputable companies such as Laboratorios Leon Farma S.A. and Chemo S.A. in France. His experience in these organizations has allowed him to apply his innovative ideas in practical settings, resulting in valuable patents that address critical health needs.

Collaborations

Perrin’s work has been enhanced through collaborations with talented professionals, including colleagues Dominique Drouin and Jose Luis Velada. These partnerships have fostered a collaborative spirit in his research endeavors, leading to fruitful innovations and advancements in the realm of synthetic progestogens.

Conclusion

In conclusion, Philippe Perrin's contributions to the field of pharmaceutical science have established him as a pivotal figure in innovation. With his expertise in synthetic progestogens and a robust patent portfolio, he continues to influence the landscape of pharmaceutical development, ultimately aiming to improve healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…